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Is ischemia the only factor predicting 
cardiovascular outcomes in all diabetes mellitus 
patients?
Mark W. Kennedy1,2, Enrico Fabris1,2, Harry Suryapranata1,2 and Elvin Kedhi1*
Abstract 
Diabetes mellitus (DM) is associated with an excess in cardiovascular morbidity and mortality, and is characterized 
by increased rates of coronary artery disease. Furthermore, once atherosclerosis is established, this is associated with 
an increased extent, complexity and a more rapid progression than seen in non-DM patients. Ischemia is the single 
most important predictor of future hard cardiac events and ischemia correction remains the cornerstone of current 
revascularization strategies. However recent data suggests that, in DM patients, coronary atherosclerosis despite the 
absence of ischemia, detected by either invasive or non-invasive methods, may not be associated with the same low 
risk of future cardiac events as seen in non-DM patients. This review seeks to examine the current evidence support-
ing an ischemia driven revascularization strategy, and to challenge the notion that ischemia is the only clinically rel-
evant factor in the prediction of cardiovascular outcomes in all-comer DM patients. Specifically, we examine whether 
in DM patients certain characteristics beyond ischemia, such as microvascular disease, coronary atherosclerosis 
burden, progression and plaque composition, may need to be considered for a more refined risk stratification in these 
high-risk patients.
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Background
An estimated 415 million people worldwide have dia-
betes mellitus (DM), with the prevalence expected to 
increase by a further 50% by 2050 [1]. DM is associated 
with an excess in morbidity and mortality [2]. Compared 
to patients without DM, people with DM are between 
two and four times more likely to have cardiovascular 
disease (CVD), with CVD accounting for a large pro-
portion of the excess mortality related to diabetes [3–7]. 
Indeed, 5-year cardiovascular mortality rates amongst 
those DM patients without a history of coronary artery 
disease (CAD) are similar to those of non-DM patients 
with a history of previous MI, and as such DM is consid-
ered a CAD equivalent [8].
Furthermore, once atherosclerosis is established, it is 
associated with increased rates, extent, complexity and 
more rapid progression than seen in non-DM patients, 
with resultant poor outcomes [9–11]. In addition, revas-
cularization outcomes in DM patients treated with per-
cutaneous coronary intervention (PCI) continue to be 
less favorable than in non-DM patients [12]. Despite 
refinements in stent design over the past number of years 
which have reduced rates of target lesion revasculariza-
tion (TLR), major adverse cardiac events (MACE) and 
stent thrombosis in non-DM patients, regrettably these 
improvements have not been transferred to DM patients, 
particularly those with more complex lesions [12, 13]. 
Alternatively, DM patients with non-complex lesions 
appear to have similar outcomes to non-DM patients, 
and so the earlier identification of these patients may 
improve outcomes and arrest progression [13]. This is 
particularly salient as for those DM patients with multi-
vessel disease, current evidence favors coronary artery 
bypass grafting (CABG) as the preferred revasculariza-
tion modality, which is likely to reflect the more com-
plete revascularization and global protection provided 
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by arterial conduits against rapid atherosclerosis progres-
sion in PCI and untreated segments.
The Providing Regional Observations Study Predictors 
of Events in the Coronary Tree (PROSPECT) study and 
subsequent sub-study analyses have consistently high-
lighted DM to be associated with worse outcomes. These 
worse outcomes in DM patients originated not only from 
the culprit lesion but also from non-culprit lesions (which 
were of very mild angiographic severity at baseline). Fur-
thermore, patients with DM were more likely to have at 
least one non-culprit lesion containing multiple high-risk 
plaque features shown to correlate with future unantici-
pated cardiac events [14, 15]. Thus, angiographically mild 
but otherwise “high risk” lesions in DM patients may not 
be as quiescent as in non-DM patients and so whilst pres-
ently the most appropriate revascularization strategy is 
based on targeting only those lesions causing ischemia, 
whether this is the only factor in DM patients is question-
able [13, 16–18]. This review seeks to examine the current 
evidence supporting an ischemia driven revascularization 
strategy, and to challenge the notion that ischemia is the 
only clinically relevant factor in the prediction of cardio-
vascular outcomes in all-comer DM patients. Specifically 
we examine whether in DM patients, certain character-
istics beyond ischemia, such as microvascular disease, 
coronary atherosclerosis burden, progression and plaque 
composition, may need to be considered for a more 
refined risk stratification in these high-risk patients.
The importance of ischemia
Studies have repeatedly shown that ischemia is the most 
important predictor of outcomes, with the presence 
of ischemia being associated with a 12-fold increased 
risk of future adverse cardiac events (death or non-fatal 
myocardial infarction) compared to those patients with-
out ischemia [19]. Furthermore, the presence of moder-
ate to severe ischemia is associated with a significantly 
higher risk of subsequent adverse events including 
death or myocardial infarction compared with mild or 
no ischemia [20]. In keeping with this, the Clinical Out-
comes Utilizing Revascularization and Aggressive Drug 
Evaluation (COURAGE) nuclear sub-study showed that 
those patients with the largest burden of ischemia, as 
detected by single-photon emission computed tomogra-
phy (SPECT), derived the greatest benefit from revascu-
larization [21]. Conversely, worsening of ischemia is an 
independent predictor of death or myocardial infarction 
[22], underscoring the concept of ischemia driven revas-
cularization, whether by PCI or CABG [23–25]. Specifi-
cally in DM patients, it has been shown that incomplete 
revascularization is associated with substantially worse 
outcomes, particularly in those patients with a large 
residual burden of ischemia [26, 27].
Fractional flow reserve and the assessment 
of ischemia
In the catheterization laboratory, fractional flow reserve 
(FFR) has emerged as the gold-standard invasive tech-
nique to detect coronary stenoses of sufficient hemo-
dynamic severity to induce myocardial ischemia. Given 
the poor correlation between angiographic severity and 
ischemic significance, the use of FFR to reliably detect 
functionally significant lesions-which may otherwise 
be left untreated with resultant poor  outcomes- seems 
logical and appealing [28]. Conversely, FFR may also 
identify those lesions which despite angiographic appear-
ances are not functionally significant and do not require 
revascularization.
In the DEFER study, intermediate coronary stenoses 
which were non-ischemic (FFR > 0.75 cut off) had a low 
risk of future adverse cardiac events; approximately 1% 
per year and this risk was not decreased by revasculariza-
tion [29]. Additionally, at 5-year follow-up, non-ischemic 
lesions continued to have significantly better outcomes 
compared to those lesions which were FFR <0.75 and had 
index revascularization (5-year event rate; 3.3 vs 15.7%, 
p = 0.002). Subsequently, the fractional flow reserve ver-
sus angiography in multi-vessel evaluation (FAME) trial, 
enrolled 1005 patients with multi-vessel CAD who were 
randomized to undergo PCI with drug-eluting stents 
guided by angiography alone or guided by FFR assess-
ment of ischemia [30]. Patients assigned to FFR-guided 
PCI underwent stenting of indicated lesions only if the 
FFR was  ≤0.80. The primary end-point was the rate of 
death, nonfatal myocardial infarction, and repeat revas-
cularization at 1  year, and was 18.3% in the angiogra-
phy group versus 13.2% in the FFR group (p = 0.02). In 
keeping with the DEFER study, those lesions which were 
found to be non-ischemic, had excellent outcomes with 
medical therapy alone; 2-year rate of myocardial infarc-
tion (MI) 0.2, 1.9% revascularization rate. Thus, based 
on these studies, limiting PCI to only ischemia induc-
ing lesions resulted in significantly better results and 
deferred revascularization of non-ischemic lesions was 
associated with excellent outcomes, in addition to signifi-
cant cost savings [31].
Moreover, similar to non-invasive studies, the 
FAME II study has shown that those lesions which are 
ischemia inducing and which are not revascularized, 
have substantially higher adverse event rates com-
pared to similar angiographic lesions which are non-
ischemic, whereas revascularization reduces this risk 
[32]. The combination of these studies have shaped 
current guidelines, recommending FFR to identify 
the hemodynamic relevance of intermediate coro-
nary lesions and deferred revascularization of those 
lesions FFR  >0.80 [25]. Unfortunately, the proportion 
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of patients with DM included in the large FFR studies 
to date has been low, ranging from 10.8 to 27%, and 
thus the concept of FFR guided revascularization in a 
population of only DM patients has perhaps not been 
completely proven.
FFR and diabetes mellitus
Diabetes mellitus is characterized by insulin resistance 
and chronic hyperglycemia, and concerns regarding 
increased vascular resistance and reduced vasodilative 
capacity due to chronic hyperglycemia have been raised 
[33]. Whilst, the reliability of FFR in DM patients is now 
accepted, more recently data has emerged suggesting 
that FFR and specifically the deferral of revascularization 
based upon a FFR >0.80 in DM patients may not be asso-
ciated with the same low risk of adverse events as seen in 
non-DM patients [34].
Our group have recently shown that compared to those 
DM patients who undergo complete revascularization, 
DM patients with  ≥1 remaining FFR negative (>0.80) 
lesion, have a significantly higher incidence of MACE, a 
composite of death/MI, rehospitalization for acute coro-
nary syndrome (ACS) and TLR, HR 2.01 (95% CI 1.21–
3.33, p  <  0.01) [35]. Furthermore, significant clustering 
of MACE events in those DM patients with a previous 
MI carrying FFR negative lesions was noted, whereas 
those patients without a previous MI had much more 
benign outcomes (Fig. 1). In a separate study, comparing 
deferred revascularization based upon a FFR >0.80 in 122 
DM patients and 128 non-DM patients, DM patients had 
significantly higher rates of target lesion failure (TLF), 
HR 3.65 (95% CI 1.40–9.53, p < 0.01), with significantly 
higher rates of TLR and a clear trend towards a higher 
incidence of target vessel MI (Fig. 2) [36]. Conversely in 
non-DM patients, deferred revascularization appeared 
to be as safe as reported in prior studies, with low rates 
of future target vessel MI and TLR. Recently, Liu et  al. 
[37] have confirmed these findings and have shown that 
amongst those patients with an FFR >0.85, diabetics had 
a more than two-fold higher risk of death and MI than 
non-diabetics, HR 2.20 (95% CI 1.19–4.01, p = 0.015). In 
addition, this study also reported that among non-dia-
betic patients with deferred PCI based upon a FFR >0.80, 
higher FFR values (closer to 1.0) were associated with 
lower rates of death, MI and revascularization. However, 
in DM patients with deferred revascularization, FFR val-
ues were unable to differentiate the risk of cardiovascu-
lar events, a finding we have recently confirmed, showing 
that FFR values do not predict future deferred lesion 
failure in FFR negative lesions in DM patients. Moreo-
ver, using multi-variate analysis, the only independent 
predictors of lesion failure identified were insulin requir-
ing DM and a history of prior revascularization, both 
conditions being marked by a more rapid atherosclerosis 
progression [38]. 
Thus, in all of these studies, deferred revascularization 
in DM patients based upon the absence of FFR detected 
Fig. 1 Time-to-event estimates for MACE, in FFR(−)MT and FFR(+)
CR groups according to presence or absence of prior MI. MACE 
major adverse cardiac event; MI myocardial infarction; FFR fractional 
flow reserve; FFR(−)MT the group of patients with ≥1 FFR negative 
(FFR > 0.80) lesion(s) which underwent medical therapy; FFR(+)CR 
the group of patients with all lesions FFR positive (FFR ≤ 0.80) and 
had complete revascularization; HR adjusted hazard ratio (Repro-
duced with permission from Kennedy et al. [35])
Fig. 2 Time-to-event estimates for target lesion failure according 
to FFR(−)DM and FFR(−)NonDM groups. TLF target lesion failure; CI 
confidence interval; HR hazard ratio (adjusted for age); FFR fractional 
flow reserve; FFR(−)DM the group of DM patients with FFR negative 
(FFR > 0.80) lesions; FFR(−)NonDM the group of Non-DM patients 
with FFR negative (FFR > 0.80) lesions (Reproduced with permission 
from Kennedy et al. [36])
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ischemia does not appear to be as safe as in non-DM 
patients. Several possible mechanisms, such as an 
increased prevalence of microvascular dysfunction, more 
aggressive atherosclerosis progression, an increased bur-
den of disease and a more active and high-risk plaque 
composition may contribute to this elevated risk of 
adverse cardiac events despite the absence of ischemia.
Complementary hemodynamic assessments 
and microvascular disease
Whilst FFR provides assessment of epicardial coronary 
stenosis severity and lesion-level ischemia, clinical events 
occur even in patients with FFR  >0.80, with one pos-
sible explanation owing to abnormalities in microvas-
culature. Coronary flow reserve (CFR) and the index of 
microcirculatory resistance (IMR) may provide additional 
complementary information in such situations. Indeed, 
significant discordance, ranging from 27 to 40%, has been 
described between FFR and CFR measurements [39, 40]. 
In a study by Meuwissen et al. [41] in patients undergo-
ing combined FFR and CFR assessment, approximately 
10% of intermediate lesions when assessed as FFR non-
ischemic, have an abnormal CFR defined as <2.0, a find-
ing confirmed by others. Recently, van de Hoef et al. [42] 
have shown that in those patients in whom a FFR >0.80 is 
associated with an abnormal CFR (<2.0), the clinical out-
comes are significantly worse than in patients with intact 
microcirculation.
Microvascular disease and DM
Data from prior studies which have assessed the micro-
circulatory function in patients with and without DM, 
have shown that patients with DM have substantially 
altered microvascular function and even amongst those 
DM patients without known CAD, the presence of an 
abnormal CFR is associated with poor outcomes, com-
parable to non-DM patients with known CAD [43, 44]. 
Furthermore, it has been demonstrated that in diabetic 
patients without obstructive CAD, coronary microvas-
cular function is substantially more impaired than in 
non-DM patients when matched for traditional cardio-
vascular risk factors [45]. Finally, in the The Prediction 
of CK-MB RElease During Successful Stenting Cor-
relating with Indicators of Microvascular ObstruC-
Tion (PREDICT) trial, despite similar pre-PCI FFR 
values, DM patients after PCI, had significantly lower 
CFR measurements indicative of greater microvascu-
lar dysfunction [46]. It has been postulated that this 
microvascular dysfunction promotes the process of ath-
erosclerosis. Indeed, this dysfunction is substantially 
worse in patients with poorer glycaemic control and 
may contribute to the poorer outcomes seen in such 
patients [47].
Recently Lee et  al. [48] examined the clinical, angio-
graphic, and hemodynamic characteristics of patients 
with high FFR (>0.80) and evaluated the prognostic 
implications of abnormal CFR and IMR in these patients. 
Despite similar clinical and angiographic characteristics, 
including similar Gensini and SYNTAX scores (to quan-
tify patients’ macrovascular disease burden), patients 
with a high FFR, a low CFR and a high IMR had a signifi-
cantly higher adverse event rate during follow-up com-
pared with those patients with intact microcirculation, 
HR: 5.623 (95% CI 1.234–25.620; p  =  0.026) (Fig.  3). 
Moreover, in a multivariate model comprising those 
patients with a high FFR, low CFR and high IMR, DM 
was identified as an independent predictor of adverse 
events, HR 2.71 (95% CI 1.05–7.02, p = 0.04). Conversely, 
those patients with a high FFR and normal microvascular 
function (high CFR, low IMR) had excellent outcomes. 
Thus, based upon this study, abnormal microvascular 
function may in part explain the worse outcomes in DM 
patients despite the absence of FFR detected ischemia, as 
has been recently described in several studies [35–37]. 
Whether the addition of complementary hemodynamic 
assessments in DM patients with negative FFR assess-
ments, may result in a more accurate deferred revascu-
larization needs to be studied in larger dedicated studies 
and the development of repeatable methods of absolute 
coronary flow measurement may finally help to provide a 
better understanding of coronary microcirculation [49].
Fig. 3 Clinical outcomes according to patterns of microvascular sta-
tus defined according to CFR and IMR among patients with high FFR. 
The cumulative incidence of patient-oriented composite outcomes 
was compared among four groups divided according to CFR and 
IMR. All IMR values were adjusted with Yong’s formula  (IMRcorr). NA 
not available; CFR coronary flow reserve; IMR index of microvascular 
resistance; CI confidence interval (Reproduced with permission from 
Lee et al. [48])
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Coronary atherosclerosis progression
Coronary atherosclerosis is a generalized disease and the 
natural history of CAD is that of a progressive condition, 
thus initially non-obstructive and non-ischemia produc-
ing lesions can over time progress to become high-grade 
stenoses, resulting in cardiac events. Several studies have 
attempted to assess the impact of atherosclerosis progres-
sion on future events. Glaser et al. [50] reported that 6% 
of initially non-culprit coronary lesions will have clinical 
plaque progression requiring non–target-lesion PCI by 
1 year. Chacko et al. [51] provided 5-year follow-up data 
from the SIRIUS (Sirolimus-Eluting Stent in De Novo 
Native Coronary Lesions) trial, and have shown that 
events attributed to the non-target vessel are frequent 
and accounted for the majority of all adverse outcomes, 
with almost 25% of patients suffering an event related to 
disease progression during the 5-year follow-up period in 
both the sirolimus and bare metal stent groups. Finally, 
the contribution of atherosclerosis progression on future 
events may be even higher; based upon the results of 
the BASKET-PRO study, 40% of all events at 5 years and 
almost 40% of all new perfusion defects in patients with-
out events were as a result of disease progression in non-
target areas [52].
Atherosclerosis progression and DM
DM is associated with even more unremitting and rap-
idly progressive atherosclerosis progression which may 
be as a result of numerous factors; hyperglycemia induced 
endothelial dysfunction, increased platelet aggregation, 
and plaque instability. Additionally when these processes 
are combined with other traditional risk factors, a syn-
ergistic effect occurs which significantly accelerates ath-
erosclerosis progression. In the Prevention of Restenosis 
with Tranilast and its Outcomes (PRESTO) trial, diabetic 
patients had a 33% increase over non-diabetic patients in 
new lesion formation over a nine month follow up [53]. 
In the SWISSI II study, despite comprehensive cardiovas-
cular risk factor intervention, DM was identified as the 
strongest predictor of progressive coronary artery disease, 
OR 19.01, p = 0.03 [54]. Finally, in the Diabetes and Siroli-
mus Eluting Stent (DIABETES) study, at 2-year follow-
up, 50% of repeat revascularizations were as a result of 
progression in a vessel or segment remote and different 
from the one previously treated, a finding which has been 
confirmed by others [55, 56]. Indeed, the aforementioned 
PROSPECT study, which assessed the natural history of 
atherosclerosis in patients presenting with ACS has high-
lighted this very fact, with the majority of subsequent 
adverse cardiac events, particularly in DM patients arising 
from so-called non-culprit lesions which given their angi-
ographic appearance (mean diameter stenosis 36.2 [31.1–
44.2]) were presumably non-ischemic at baseline [14].
This more rapid progression may in part explain 
the findings of the recent studies which have shown 
worse outcomes in DM patients despite the absence 
of ischemia. Furthermore, it is recognized that lesions 
which are angiographically significant are known to pro-
gress faster than milder lesions [57]. Thus, despite the 
absence of ischemia, an “angiographically significant 
but hemodynamically non-significant” lesion in the set-
ting of rapid atherosclerosis progression in DM, may not 
be insignificant. Indeed, Giri et al. [58] have shown in a 
study of 4755 patients undergoing SPECT myocardial 
perfusion imaging (MPI), of which 929 were diabetic, 
that survival during the first 2  years of follow-up was 
identical in the patients with normal MPI results, irre-
spective of their diabetic status. However rates increased 
rapidly after 2 years in diabetics but not in non-diabetics 
(Fig. 4). Thus, the absence of ischemia, assessed either by 
invasive (FFR) or non-invasive (SPECT) methods in DM 
patients, does not appear to have the same “warranty” as 
in non-DM patients.
Coronary artery disease burden and DM
Compared to non-DM patients, DM is associated with a 
higher incidence of coronary artery calcium (CAC), an 
anatomic marker of increased coronary artery disease 
burden. Furthermore, non-invasive studies combining 
computerized tomography (CT) CAC scoring and a func-
tional assessment of myocardial ischemia in the same 
patient, have shown that atherosclerotic burden despite 
normal ischemia studies predicts adverse cardiac events. 
Thus, there exists a strong linear relationship between 
increasing CAC scores and future adverse cardiac events, 
Fig. 4 Kaplan-Meier survival curves comparing the subset of diabetic 
and nondiabetic patients with normal stress MPI results. MPI myocar-
dial perfusion imaging (Reproduced with permission from Giri et al. 
[58])
Page 6 of 9Kennedy et al. Cardiovasc Diabetol  (2017) 16:51 
with a CAC score >400 being a significant predictor, HR 
3.55 (95% CI 1.78–7.09; p  <  0.001). Alternatively, those 
patients with normal perfusion and without CAC have 
excellent outcomes.
The Multi-Ethnic Study of Atherosclerosis (MESA) in 
which 6814 participants without a prior history of CAD 
underwent CT assessment to assess the incidence of CAC, 
showed that compared to non-DM patients, DM patients 
have double the incidence of CAC presence, RR 1.9 (95% 
CI 1.4–2.4, p < 0.01). Furthermore, DM was identified as 
the strongest risk factor for CAC progression, HR 26.8 
(95% CI 19.5–34.2, p  <  0.001). Conversely, 38% of DM 
patients had no CAC, and the absence of CAC was asso-
ciated with a low annual rate (<1%) of CHD events (7). 
Recently, Blanke et  al. [59] published 5-year follow up 
of the prognostic utility of coronary CT angiography in 
patients with DM from the CONFIRM (Coronary CT 
Angiography Evaluation for Clinical Outcomes: An Inter-
national Multicenter) registry. In this study, 1823 DM were 
propensity-matched to 1823 patients without DM. In the 
absence of CAD, DM patients had similar outcomes to 
non-DM patients, HR 1.32 (95% CI 0.78–2.24; p = 0.30). 
However, strikingly patients with DM and non-obstructive 
(diameter stenosis 1–49%) and thus highly likely non-
ischemic CAD, had significantly worse outcomes than 
non-DM patients with obstructive disease (diameter ste-
nosis > 50%), both in terms of all-cause mortality, [HR 2.09 
(95% CI 1.43–3.06, p < 0.001)] and MACE [HR 5.12 (95% 
CI 2.95–8.88, p < 0.001)]. These landmark findings strongly 
support the concept that DM is associated with therapy 
refractive, rapidly progressive coronary atherosclerosis and 
further supports the possibility that such progression may 
be as a result of significant differences in plaque compo-
sition between DM and non-DM patients, as described in 
the PROSPECT study [11, 14, 15].
DM and plaque composition
Marso et al. [15] in a sub-study analysis from the PROS-
PECT study, have shown that DM patients have a 
significantly different composition and character of ath-
erosclerosis than non-DM patients. Using gray-scale 
and radio-frequency intravascular ultrasound, non-cul-
prit lesions (NCL) in DM patients were noted to be sig-
nificantly longer, had a greater plaque burden, a smaller 
lumen area, and had a greater necrotic core and a larger 
calcium content. Additionally, necrotic core and calcifica-
tion were significantly greater in the NCL’s of those DM 
patients with future MACE compared to DM patients 
who did not have subsequent event. Furthermore, the use 
of insulin therapy was also noted to be associated with a 
significantly higher incidence of NCL-MACE [14].
In an additional analysis from the PROSPECT study, 
Kedhi et  al. [60] analyzed the incidence of NCL-MACE 
in two propensity-matched groups according to the pres-
ence of DM and thin cap fibroatheroma (TCFA). In this 
study, among DM patients, the presence of  ≥1 TCFA 
was associated with higher NCL-MACE at 3 years (27.8 
vs. 8.9% in patients without a TCFA, HR: 3.56; 95% CI 
0.98–12.96; p  =  0.04). Alternatively, DM patients with-
out a TCFA had a similar 3-year rate of NCL-MACE as 
patients without DM (8.9 vs. 8.9%; HR:1.09; 95% CI 0.27–
4.41; p = 0.90) (Fig. 5). Thus based upon this study, there 
would appear to be a symbiotic relationship between 
vulnerable plaque and DM, which results in excessive 
adverse outcomes which does not occur to the same 
degree in non-DM patients with similar plaque.
Moreover, studies have shown that a longer duration 
of DM and poorer glycemic control are associated with 
a higher prevalence of TCFA [61, 62]. Since DM not 
only promotes atherosclerosis progression, the greater 
oxidative stress and hyperglycemia associated with this 
condition also favors plaque instability and degradation 
[63, 64]. Given the higher prevalence of TCFA in DM 
patients, this may account for the observed elevated risk 
despite an apparent absence of ischemia. The Impact of 
optical coherence tomography (OCT) detected TCFA on 
major adverse events derived from non-ischemic (FFR 
negative) atherosclerotic lesions in DM patients is cur-
rently being studied in the COMBINE study [65]. In this 
prospective multi-center, study, DM patients with FFR-
negative lesions are clinically followed after index OCT 
assessment and compared for major adverse events based 
on presence or absence of TCFA. Interestingly, both 
Fig. 5 Time-to-event estimates of non-culprit lesion-related MACE, 
according to the presence of diabetes and/or a TCFA at 3 years in the 
propensity matched groups of patients with and without diabetes. 
DM diabetes mellitus. TCFA thin-cap fibroatheroma. HR hazard ratio. 
CI confidence interval. NCL non-culprit lesion. MACE major adverse 
cardiac events (Reproduced with permission from Kedhi et al. [60])
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groups will be compared with a third group of patients 
with similar angiographic lesions at baseline which were 
FFR positive and therefore underwent index revascu-
larization. This study will shed important light onto the 
impact of untreated TCFA in FFR negative lesions and 
may help to explain the poorer outcomes observed in 
these non-ischemic lesions.
Finally, in response to progressive atherosclerosis, 
negative remodeling occurs more frequently in DM 
patients compared to the typical positive remodeling 
seen in non-DM patients [66]. This vessel shrinkage 
and inability to overcome continued intimal hyperplasia 
may also explain why FFR and other ischemic tests do 
not appear to carry the same warranty. Moreover, nega-
tive remodeling has been shown to be a marker of more 
advanced atherosclerosis and more abundant TCFA 
distribution which may also contribute to the reduced 
guarantee [67, 68].
Conclusions
DM patients have more rapidly progressive coronary ath-
erosclerosis, a higher degree of microvascular disease, 
a larger burden of coronary plaque and a significantly 
different composition of atherosclerosis compared to 
non-DM patients. Recent evidence has shown that the 
absence of ischemia, detected by either non-invasive or 
invasive methods, may not carry the same “warranty” as 
in non-DM patients. This finding should make us rethink 
our strategy when dealing with coronary atherosclerosis 
in DM patients. The use of ischemic assessments, intrac-
oronary morphological imaging, as well as our treatment 
modalities need to be fine-tuned to match the specific 
needs of this patient population, which is clearly quite 
different than the non-DM population. In this endeavor 
ischemia is only one, but clearly not the only factor to 
take into account. Ongoing trials will shed more light 
into this fascinating model of human atherosclerosis 
progression.
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